SEARCH

SEARCH BY CITATION

References

  • 1
    Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:14171426.
  • 2
    Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. Allergy 2010;65:290295.
  • 3
    Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:14271443.
  • 4
    Peroni A, Colato C, Zanoni G, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases J Am Acad Dermatol 2010;62:557570; quiz 571–572.
  • 5
    Van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:8798.
  • 6
    Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008;24:15771582.
  • 7
    van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008;87:301310.
  • 8
    Aksentijevich I, C DP, Remmers EF, Mueller JL, Le J, Kolodner RD et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:12731285.
  • 9
    Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007;19:615622.
  • 10
    Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319325.
  • 11
    Nakamura Y, Kambe N, Saito M, Nishikomori R, Kim YG, Murakami M et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 2009;206:10371046.
  • 12
    Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581592.
  • 13
    Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:24432452.
  • 14
    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:24162425.
  • 15
    Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:20952102.
  • 16
    Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, Wittkowski H, Bialkowski A, Tzaribachev N et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63:840849.
  • 17
    Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:24322442.
  • 18
    Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaloïde?). J Dermatol Angers 1972;Cas cliniques No 46 B:Abstract 46.
  • 19
    Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001;80:3744.
  • 20
    de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137148.
  • 21
    Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010;5:38.
  • 22
    Asli B, Brouet JC, Fermand JP. Spontaneous remission of Schnitzler syndrome. Ann Allergy Asthma Immunol 2011;107:8788.
  • 23
    Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009;48:13041308.
  • 24
    Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.. Arthritis Rheum 2005;52:22262227.
  • 25
    Schneider SW, Gaubitz M, Luger TA, Bonsmann G. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 2007;56(5 Suppl):S120S122.
  • 26
    Dybowski F, Sepp N, Bergerhausen HJ, Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 2008;26:354357.
  • 27
    de Koning HD, Schalkwijk J, van der Meer JW, Simon A. Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011;128:13521354.
  • 28
    Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012;67:943950.
  • 29
    Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008;105:16141619.
  • 30
    Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011;63:830839.
  • 31
    Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424430.
  • 32
    Yamamoto T. Cutaneous manifestations associated with adult-onset Still's disease: important diagnostic values. Rheumatol Int 2012;32:22332237.
  • 33
    Riera E, Olive A, Narvaez J, Holgado S, Santo P, Mateo L et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol 2011;29:331336.
  • 34
    Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007;3:328335.
  • 35
    Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377:21382149.
  • 36
    Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545555.
  • 37
    Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557567.
  • 38
    Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747754.
  • 39
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:9981006.
  • 40
    Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis–from pathophysiology to treatment. Rheumatology (Oxford) 2008;47:121125.
  • 41
    Stoffels M, Simon A. Hyper-IgD syndrome or mevalonate kinase deficiency. Curr Opin Rheumatol 2011;23:419423.
  • 42
    Rezaei N. TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder. Clin Rheumatol 2006;25:773777.
  • 43
    Weller K, Viehmann K, Brautigam M, Krause K, Siebenhaar F, Zuberbier T et al. Cost-intensive, time-consuming, problematical? How physicians in private practice experience the care of urticaria patients J Dtsch Dermatol Ges 2012;10:341347.
  • 44
    Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009;88:2331.
  • 45
    Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848850.
  • 46
    Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011;63:11511155.
  • 47
    Kallinich T, Wittkowski H, Keitzer R, Roth J, Foell D. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis 2010;69:677682.
  • 48
    Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:23612371.
  • 49
    Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206:10291036.
  • 50
    Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:33403348.
  • 51
    Ait-Idir D, Khilan A, Djerdjouri B, El-Shanti H. Spectrum of mutations and carrier frequency of familial Mediterranean fever gene in the Algerian population. Rheumatology (Oxford) 2011;50:23062310.
  • 52
    Gattorno M, Sormani MP, D'Osualdo A, Pelagatti MA, Caroli F, Federici S et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008;58:18231832.
  • 53
    Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001;108:615620.
  • 54
    Gandhi C, Healy C, Wanderer AA, Hoffman HM. Familial atypical cold urticaria: description of a new hereditary disease. J Allergy Clin Immunol 2009;124:12451250.
  • 55
    Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004;24:259286, vii.
  • 56
    Kivity S, Schwartz Y, Wolf R, Topilsky M. Systemic cold-induced urticaria–clinical and laboratory characterization. J Allergy Clin Immunol 1990;85(1 Pt 1):5254.